Solvent cast film sustained release latanoprost implant

• US 8,715,713 B2
• Filed: 04/27/2012
• Issued: 05/06/2014
• Est. Priority Date: 04/29/2011
• Status: Active Grant

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: Ghebremeskel, Alazar N., Spada, Lon T.
• Primary Examiner(s): BARHAM, BETHANY P
• Application Number:
  US13/457,785
• Publication Number:
  US 20120276184A1
• Time in Patent Office: 739 Days
• Field of Search: None
• US Class Current: 424/428
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 31/216 of acids having aromatic rings, e.g. benactizyne, clofibrate
• CPC Class Codes: A61K 31/5575 having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/7007 Drug-containing films, membranes or sheets A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics

Abstract

The present invention provides a sustained release latanoprost implant in the form of a thin film comprising latanoprost incorporated in a biodegradable polymer matrix. Preferably, said implant is an intraocular implant comprising a thin film comprising latanoprost incorporated in a biodegradable polymer matrix wherein said implant is configured as a disc or a rolled film that can be inserted into the eye and unrolls to provide a film having a high surface area to volume ratio.

Claims

1. A biodegradable implant for reducing intraocular pressure in an eye of an individual in need thereof, the implant consisting of about 30% by weight latanoprost, about 35% by weight R208, which is an ester terminated poly(D,L-lactide) having an inherent viscosity of about 1.8-2.2 dl/g, and about 35% by weight RG755, which is an ester terminated poly(D,L-lactide-co-glycolide) having an inherent viscosity of about 0.50-0.70 dl/g and a D,L-lactide:

glycolide ratio of about 75;

25, wherein the implant is in the form of a rolled film that, once inserted into an eye, can unfurl to its original shape to thereby expose its entire surface to provide for drug diffusion out of the film into the eye, and wherein the implant releases latanoprost continuously for at least 30 days after placement in the eye of the individual.

3. A method for making a biodegradable intraocular implant according to claim 1 or 2, the method comprising:

a) combining latanoprost and the biodegradable polymers in a receptacle;

b) mixing the latanoprost and biodegradable polymers in the receptacle using a spatula to form a mixture;

c) transferring the mixture to a glass culture dish;

d) dissolving the dish mixture in a solvent selected from the group consisting of dichloromethane, ethyl acetate, chloroform, acetone, and acetonitrile, to form a solution;

e) casting the solution into a dish;

f) drying the cast for about 24 hours to form a film;

g) cutting the film into circular portions of about 4 mm in diameter;

h) rolling said circular portions to form a rolled film for placement in the eye of an individual in need thereof, wherein the rolled film, once inserted into an eye, can unfurl to its original shape to thereby expose its entire surface to provide for drug diffusion out of the film into the eye.

4. A biodegradable implant according to claim 1 or 2, wherein said film is about 100 μ

m to about 500 μ

m thick and about 2 mm to about 6 mm in diameter.

2. A biodegradable implant for reducing intraocular pressure in an eye of an individual in need thereof, the implant consisting of about 30% by weight latanoprost, about 35% by weight R208, which is an ester terminated poly(D,L-lactide) having an inherent viscosity of about 1.8-2.2 dl/g, and about 35% by weight R203S, which is an ester terminated poly(D,L-lactide) having an inherent viscosity of about 0.25-0.35 dl/g, wherein the implant is in the form of a rolled film that, once inserted into an eye, can unfurl to its original shape to thereby expose its entire surface to provide for drug diffusion out of the film into the eye, and wherein the implant releases latanoprost continuously for at least 30 days after placement in the eye of the individual.